Vivos (RDGL) Return on Sales (2010 - 2025)

Vivos (RDGL) posted Return on Sales of 0.44% for Q4 2025, up 83.86% sequentially from 2.7% in Q3 2025, and up 161.0% YoY from 0.17% in Q4 2024.

Vivos (RDGL) Return on Sales (2010 - 2025) Analysis & Trends

Vivos has reported Return on Sales for 15 years, with the latest figure at 0.44% in Q4 2025.

Quarterly Return on Sales rose 161.0% year-over-year to 0.44% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.45% (up 59.0% YoY) and the FY2025 annual result came in at 0.45%, up 59.0% from the prior year.
Return on Sales grew to 0.44% in Q4 2025 per RDGL's latest filing, from 2.7% in the prior quarter.
Over five years, Return on Sales peaked at 0.14% in Q3 2021 and troughed at 2.7% in Q3 2025.
A 5-year average of 0.97% and a median of 0.85% in 2022 frame the typical range for Return on Sales.
The widest YoY moves for Return on Sales: up 161 bps in 2025, down 105 bps in 2025.
Over 5 years, Return on Sales stood at 1.15% in 2021, then grew by 6 bps to 1.09% in 2022, then slumped by 37 bps to 1.48% in 2023, then tumbled by 38 bps to 2.05% in 2024, then soared by 79 bps to 0.44% in 2025.
According to Business Quant data, Return on Sales over the past three periods registered 0.44%, 2.7%, and 0.43% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Abbott Laboratories	200.51 Bn	194.91 Bn	7.27 Bn	0.00%
2	Stryker	129.96 Bn	126.48 Bn	4.50 Bn	0.00%
3	Medtronic	120.18 Bn	110.96 Bn	6.41 Bn	0.00%
4	Boston Scientific	74.28 Bn	73.74 Bn	3.85 Bn	0.00%
5	Edwards Lifesciences	52.75 Bn	48.50 Bn	1.35 Bn	0.00%
6	Dexcom	34.67 Bn	32.73 Bn	830.00 Mn	0.00%
7	GE HealthCare Technologies	34.23 Bn	32.12 Bn	2.18 Bn	0.00%
8	Koninklijke Philips	26.46 Bn	23.14 Bn	4.55 Bn	0.00%
9	Steris	23.30 Bn	22.82 Bn	684.20 Mn	0.00%
10	Vivos	24.90 Mn	23.34 Mn	-3,105.00	-0.44%

Download Data